Biogen quickly became the leader in the multiple sclerosis market, growing Avonex into a billion-dollar drug. Now Biogen's dominance is being challenged by Serono and its new partner Pfizer, co-promoting another interferon, Rebif, which came to market with head-to-head data showing it's better. Biogen maintains that Avonex is the best treatment, and is working to support its contention. The biotech is confident that the relationships it has built over time, and strengthened through services, will be hard for newcomers to push aside. The potential for leverage is what attracts Pfizer to this specialist market: it aims to sell Rebif broadly. Its 300 neurology sales reps will carry other products for the co-morbidities MS patients suffer--so the ROI could be good, even if Rebif itself isn't a huge seller. An industry whose pipeline is far richer in niche than GP products will be watching this marketing battle: will Biogen's focus carry the day--or can Pfizer turn a late-entry specialist product into a market leader and in the process, make significant money for itself?
Deborah Erickson
Biogen Inc. has made its fortune by promoting a single drug, Avonex, its own version of interferon beta-1a, as...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
